Back to top

crispr: Archive

Zacks Equity Research

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.

ALKSNegative Net Change VRTXPositive Net Change CRMDNegative Net Change CRSPNegative Net Change